2Jansen WJ,Zwart B,Hulscher ST,et al.CPT-11 in human colon cancer cell lines and xenografts:characterization of cellular sensitivity determinants[J].Int J Cancer,1997,70(3):335-340.
二级参考文献16
1Rowe PM. Camptothecins: new enthusiasm for an old drug.Lancet, 1995,347:892.
2Slichenmyer WJ, Rowinsky EK, Donehower RC, et al.The current status of camptothecin analogues as antitumor agents,J Natl Cancer Inst,1993,85:271.
3Bleiberg H. Colorectal cancer: the challenge, Eut J Cancer,1996,32(A Suppl 5):S2.
4Labianca R, Pessi A, Facendola G, et al. Modulated 5-fluorouracil (5-FU) regimens in advanced colorectal cancer:a critical review of comparative studies. Eur J Cancer,1996,32(A Suppl5):S7.
5Shimada Y, Rougier P, Pitot H. Efficacy of CPT-11(irinotecan) ad a single agent in metastatic colorectal cancer.Eur J Cancer,1996,32(A Suppl3):S13.
6Wiseman LR, Markham A. Irinotecan. A review of its pharma cological properties and clinical efficacy in the management of advanced colorectal cancer.Drugs,1996,52:606.
7Armand JP, Ducreux M, Mahjoubi M, et al. CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur J Cancer,1995,31(A Suppl 3):1283.
8Cunningham D. Current status of colorectal cancer:CPT-11(irinotecan), a therapeutic innovation. Eur J Cancer, 1996,32(A Suppl 3):S1.
9Rougier P, Bugat R. CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. Semin Oncol,1996,23(1Suppl3):34.
10Saltz L, Shimada Y, Khayat D. CPT-11 (irinotecan)and 5-fluorouracil:a promising combination for therapy of colorectal cancer. Eur J Cancer, 1996,32(A Suppl 3):S24.
